ZAI LAB LTD. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ZAI LAB LTD. - More news...
ZAI LAB LTD. - More news...
- Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
- Zai Lab Announces Participation in February Investor Conferences
- Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
- Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
- Zai Lab Appoints Michel Vounatsos To Its Board of Directors
- Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
- Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
- Zai Lab Announces Participation in January Investor Conferences
- Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
- Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
- Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
- Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
- Zai Lab Launches its first Trust Report
- Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
- Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting
- Zai Lab Announces Participation in September Investor Conferences
- Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates
- Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
- Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
- Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
- Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
- Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
- Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
- Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
- Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
- Zai Lab Announces Upcoming Presentations at June Investor Conferences
- Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022
